This morning, Morgan Stanley lowered its EPS estimates on shares of Cree (NASDAQ:CREE) through 2013 as operating costs are on the rise at the company. In the report, Morgan Stanley maintained its overweight rating and its $35 price target.
Shares of Cree were sharply lower on Monday, falling 7.9% so far.
And UBS lowered its price target on shares of Johnson & Johnson (NYSE:JNJ) to $72 as the company continues to struggle with generics. While UBS maintained its buy rating on the stock, it did lower its EPS estimates in the report.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.